We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Celadon Pharmaceuticals Plc | LSE:CEL | London | Ordinary Share | GB00BDQYGP38 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 101.50 | 98.00 | 105.00 | 101.50 | 101.50 | 101.50 | 11,347 | 08:00:05 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Investment Advice | 24k | -17.01M | -0.2722 | -3.73 | 63.41M |
From May 2022 to May 2024
TIDMCEL
RNS Number : 4321N
Celadon Pharmaceuticals PLC
31 May 2022
Celadon Pharmaceuticals Plc
("Celadon" or the "Company")
Publication of Annual Report and Notice of Annual General Meeting
Celadon Pharmaceuticals Plc, a leading UK based pharmaceutical company focused on the development and supply of natural cannabis-based medicines, announces that copies of the 2021 Annual Report and Accounts, together with its Notice of 2022 Annual General Meeting ("AGM"), were posted to shareholders today and are available for viewing on the Company's website www.celadonpharma.com .
The Company will be holding its AGM at 4.00pm on Monday 27 June 2022 at the Edgbaston Park Hotel and Conference Centre, 53 Edgbaston Park Road, Birmingham, B15 2RS.
Enquiries:
Celadon Pharmaceuticals Plc James Short Via Powerscourt Arthur Wakeley Canaccord Genuity Limited (Nominated Adviser and Broker) Andrew Potts / Patrick Dolaghan +44 (0)20 7523 8000 Powerscourt Group Sarah MacLeod / Nick Johnson / Sam Austrums +44 (0)20 7250 1446 / celadon@powerscourt-group.com Ibrahim Khalil
About Celadon Pharmaceuticals Plc
Celadon Pharmaceuticals Plc is a UK based pharmaceutical company focused on the research, cultivation, manufacturing, and supply of natural cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism. Its 100,000 sq. ft UK facility comprises a laboratory designed to meet GMP standards, and capacity for a large indoor hydroponic growing facility that has received a Home Office License to legally grow high-THC medicinal cannabis for the purpose of producing test batches of cannabis oil to support its application to the MHRA. The Company's subsidiary, LVL, owns a MHRA conditionally-approved cannabis trial using cannabis based medicinal products to treat chronic pain in the UK.
For further information please visit our website www.celadonpharma.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NOABKDBNBBKDKPN
(END) Dow Jones Newswires
May 31, 2022 08:30 ET (12:30 GMT)
1 Year Celadon Pharmaceuticals Chart |
1 Month Celadon Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
